Second, there is no specific treatment with a demonstrated high impact on survival for these AMLs, as there is for APL, although it could be argued that gemtuzumab‐ozogamicin appears to benefit patients with AML with CBFB::MYH11 [24]. This evidence concerns the gene MYH11 and acute myeloid leukemia.